Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash & Equivalents (2018 - 2025)

TransMedics has reported Cash & Equivalents over the past 8 years, most recently at $488.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $488.4 million for Q4 2025, up 45.07% from a year ago — trailing twelve months through Dec 2025 was $488.4 million (up 45.07% YoY), and the annual figure for FY2025 was $488.4 million, up 45.07%.
  • Cash & Equivalents for Q4 2025 was $488.4 million at TransMedics, up from $466.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TMDX hit a ceiling of $582.2 million in Q2 2023 and a floor of $17.9 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $330.1 million (2024), compared with a mean of $263.3 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 50.51% in 2021 and later skyrocketed 1816.01% in 2023.
  • TransMedics' Cash & Equivalents stood at $25.6 million in 2021, then soared by 686.48% to $201.2 million in 2022, then soared by 96.25% to $394.8 million in 2023, then dropped by 14.73% to $336.6 million in 2024, then surged by 45.07% to $488.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $488.4 million (Q4 2025), $466.2 million (Q3 2025), and $400.6 million (Q2 2025) per Business Quant data.